Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Prolactinoma 2Recurrence 1Pituitary Neoplasms 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Recurrence × Cabergoline × Clear all
NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Seoul National University Hospital

Phase NA Unknown
68 enrolled
Endocrine

Pituitary Neoplasms, Recurrence, Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡